Alkyl Amines Q2 FY27: PAT +52% YoY as margins expand, but cools 31% QoQ off Q1 peak
PAT +51.77% YoY · revenue +26.08% · margins expanding
₹490.95 Cr
+26.08% YoY
₹65.17 Cr
+51.77% YoY
12.99%
+2.2pp YoY
₹12.74
Alkyl Amines' standalone PAT came in at ₹65.17 Cr on revenue from operations of ₹490.95 Cr for the September 2026 quarter. Year-on-year — the primary read — revenue grew 26.1% (₹389.41 Cr) and PAT grew a faster 51.8% (₹42.94 Cr), with net margin expanding to 13.0% from 10.8% and operating margin to 19.9% from 18.0%. Sequentially the print is softer: revenue fell 7.0% and PAT fell 31.1% against Q1 FY27 (revenue ₹528.01 Cr, PAT ₹94.63 Cr, OPM 25.3%), but Q1 was itself an exceptionally strong base — the company had flagged PAT +91% YoY and margin expansion to 25.3% that quarter — so the QoQ dip reads as reversion rather than fresh deterioration; no exceptional items appear in any of the compared quarters.
Q2 FY-2027 vs prior quarters
The margin bridge sits mostly on operating leverage: cost of materials consumed eased to 53.1% of revenue from operations (versus 59.9% in Q1 and 49.2% a year ago), but employee costs (₹33.95 Cr) and other expenses (₹90.16 Cr) held roughly flat in absolute terms versus Q1 (₹36.31 Cr and ₹90.05 Cr), so the 7% QoQ revenue decline compressed operating margin from Q1's elevated 25.3% to 19.9% — still above the year-ago 18.0%. Tax worked out to ₹24.92 Cr on PBT of ₹90.09 Cr (effective rate 27.7%), in line with recent quarters.
The stock went into the print at ₹1,637.5, down 6% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
What the summary numbers don't show
EPS (basic) ₹12.74 for the quarter, down from ₹18.50 in Q1 FY27, up from ₹8.40 a year ago.
Management projects 5% to 10% volume growth for the upcoming year, with top-line revenue expected to be significantly higher due to elevated product prices. They express cautious optimism that margins have bottomed out and will see improvement, driven by passing on higher raw material costs. Capex will be limited to co
— This quarter: met
No public analyst consensus for this quarter turned up in search, so vs-street is unknown rather than assumed. Against management's own May 2026 concall guidance — 5-10% volume growth for the year, revenue significantly higher on elevated prices, and margins bottoming out with room to improve — this print is broadly on-track: YoY revenue and margin both moved in the guided direction, though the QoQ pullback means the margin recovery is not yet linear. No management press release commentary was available in the context to cross-check against. Separately, the stock saw a trading-volume spike in early October that drew a BSE clarification request (company confirmed no undisclosed price-sensitive information) — unrelated to this result. On the balance sheet, the company drew ₹19 Cr of secured borrowings for the first time in recent periods and capital work-in-progress rose to ₹159.53 Cr from ₹130.48 Cr, with H1 FY27 capex of ₹36.72 Cr tracking within the ₹80-90 Cr full-year guided band.
W1
Whether OPM holds near the YoY-expanded 18-20% band or reverts further from Q1's 25.3% peak, per management's guidance that margins have bottomed and will improve.
W2
H2 FY27 capex pace against the ₹80-90 Cr full-year guidance, with ₹36.72 Cr spent in H1.
W3
Whether full-year revenue growth tracks management's guided 5-10% volume growth with higher realizations, given this quarter's 7% QoQ revenue dip.
Standalone only — company has no subsidiary/associate/JV this quarter (note 7); no exceptional items in current, Q1 FY27 or year-ago columns; PBT−tax reconciles exactly to reported PAT.
Informational and educational content only. Not investment advice.